ClinicalTrials.gg
RecruitingNCT05931497Updated Nov 13, 2025

Sauna for Long Covid

An interventional study of whole body hyperthermia in Long COVID, sponsored by Massachusetts General Hospital. Recruiting at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-11-13.

Sponsored by Massachusetts General Hospital · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
21
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 195 studies in Post-Acute COVID-19 Syndrome with a site in United States — 63 open to participants now, 85 under way, 7 of them phase 3. Post-Acute COVID-19 Syndrome · United States.

Planned enrollment
117th of 156
21 · median 53
Started
2026
with 13 others
No phase
78 of 195
23 open now
Primary completion
2026-09
later than 26 of 84 live
Registered
92nd of 195
by date
Lead sponsor
5 of 195
Massachusetts General Hospital

Among the 195 studies in Post-Acute COVID-19 Syndrome with a site in United States, this one is the 117th largest by planned enrollment of the 156 interventional ones that give a count, is one of 14 that started in 2026, is one of 78 with no phase, reaches primary completion later than 26 of the 84 other live ones, and was the 92nd registered.

Post-Acute COVID-19 Syndrome

606 studies on the registry are indexed under Post-Acute COVID-19 Syndrome; 201 are open to participants now.

Browse Post-Acute COVID-19 Syndrome studies →

Open to participants now

63 of the 195 studies in Post-Acute COVID-19 Syndrome with a site in United States are open now. Recruiting first, the newest first:

57 more — sign in →

All 63 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 144 Post-Acute COVID-19 Syndrome studies recruiting now, 69 (48%) set no upper age limit and 53 (37%) stop at 75 or younger; 15 take children under 18; 39 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 195 studies in Post-Acute COVID-19 Syndrome with a site in United States, or all of them as a file.
02

Study summary

Research suggests that Whole Body Hyperthermia in a sauna-like environment can reduce symptoms related to post-acute sequelae of SARS-CoV-2 (PASC), or Long Covid. The investigators aim to study the feasibility and treatment effect of this procedure for patients experiencing Long Covid symptoms.

Read the detailed description

This proposed trial will examine, for the first-time, study whole-body hyperthermia (WBH) as a treatment for PASC. The investigators will enroll 21 people with PASC who will be randomized into two conditions with different temperature WBH. The primary aims will explore acceptability and feasibility, reduction of fatigue (primary symptom), and potential mechanisms (inflammation and sleep). Inflammation and sleep have both been shown to be dysregulated in PASC and addressed by WBH in other populations. The investigators will use week 2 as the primary endpoint. However, patients will be followed for 4 and 6 weeks to monitor the duration of effect.

03

Conditions studied

  • Long COVID
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 18-65 years of age
  2. English language proficiency
  3. Ability to provide
  4. Ability to lie supine (on back) for 2 hours (required for sauna sessions)
  5. Must have had clinically suspected COVID-19 and a positive antibody test or a documented SARS-CoV-2 infection (a positive reverse transcription polymerase chain reaction test) at least 12 weeks prior to Screening (Note: clinician judgment can override lack of positive COVID test with clear Long Covid onset and presentation)
  6. The Patient Reported Outcome Measurement Information System Fatigue-Short Form v1.0 -Fatigue 7a (PROMIS F-SF43) raw score of 21 or greater at Screening (onset of fatigue confirmed post-infection as in other studies of PASC)
  7. Individuals of must use an acceptable form of .

Exclusion criteria

Exclusion Criteria:

  1. Fatigue for known reasons other than PASC (e.g. longstanding diagnosis of Chronic Fatigue Syndrome pre-dating Long Covid, low thyroid, multiple sclerosis, AIDS related fatigue, mononucleosis), as determined by clinical discretion of study investigators
  2. Known to infrared heat exposure, significant history of heat stroke
  3. Breastfeeding, pregnancy or planned pregnancy during study
  4. Active suicidal intent
  5. History of bipolar disorder, psychotic disorders, eating disorders, obsessive compulsive disorder, and/or substance use or dependence (within the last year), as per the Mini-International Neuropsychiatric Interview (MINI)44
  6. Positive urine toxicology screen for illicit drug use
  7. Any serious unstable medical condition
  8. Inability to fit into the sauna device. Morbid obesity ( > 40) and/or body shape that might increase the risk of cutaneous burning from the device (because of skin being too close to the heat).
  9. Back pain that would interfere with ability to lay on hard surface
  10. Using medication that might impact thermoregulatory capacity and cannot be held for an appropriate length (at least one half-life) as determined by clinician judgment prior to receiving WBH treatment
  11. Breast Implants
  12. Claustrophobia that would interfere with ability to remain in sauna
  13. Unsafe cardiac status as defined by abnormal reading at screening visit or as determined by study doctor or subject's physician
  14. History of or current diagnosis of thrombosis or thrombophilia
  15. History of hemophilia
  16. History of febrile seizures or seizure disorders
  17. Any new treatments/medications for long-COVID that have started in the past 3 months
  18. A subject who in the opinion of the Principal Investigator would not be able to safely complete the study or would jeopardize study integrity.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
21 participants (estimated)

Study arms

  • Experimental
    verum whole body hyperthermia

    WBH will be completed with a Clearlight Sauna Dome and ancillary equipment to monitor core body temperature. For the verum WBH, participants will be brought to a core body temperature of 101.3°F.

    Device: whole body hyperthermia

  • Sham comparator
    sham whole body hyperthermia

    The sham condition will be identical to the active WBH condition. Time and other procedures will be consistent. Mild heat will be used to mimic an active WBH session.

    Device: whole body hyperthermia

Interventions

  • Devicewhole body hyperthermia

    heat will be applied to the participant through a sauna to increase core body temperature

06

What researchers measure

Primary outcomes

  1. The Patient Reported Outcome Measurement Information System Fatigue-Short Form v1.0 -Fatigue 7a (PROMIS F-SF)

    provides a more in depth assessment of fatigue as compared to the PROMIS 29 and consists of 7 items that measure both the experience of fatigue and the interference of fatigue on daily activities over the past week. Uses a range of 7-35, higher scores indicate higher fatigue.

    Time frame: 2-weeks (primary endpoint) follow up at 6 weeks

Secondary outcomes

  1. Patient-Reported Outcomes Measurement Information System (PROMIS-29)

    assesses seven health domains (i.e., physical function, fatigue, pain interference, depressive symptoms, anxiety, ability to participate in social roles and activities, and sleep disturbance) using four items per domain. There is no total score, and scores range from 4-10 for each health domain (with 4 items for each of the 7 health domains). Scores are transformed into t scores with higher scores indicating better health.

    Time frame: 2-weeks (primary endpoint) follow up at 6 weeks

  2. Patient Health Questionnaire-9 (PHQ)

    a well-established, brief self-administered 9-item depression screening and monitoring tool. Uses a range of 0-27 with higher scores indicating greater depressive symptoms.

    Time frame: 2-weeks (primary endpoint) follow up at 6 weeks

  3. The Perceived Stress Scale (PSS)

    consists of 10 items and measures the frequency with which perceived stressful life situations are experienced. Scores can range from 0 to 40 with higher scores indicating higher perceived stress.

    Time frame: 2-weeks (primary endpoint) follow up at 6 weeks

  4. Patient-Reported Outcomes Measurement Information System Cognitive Abilities

    items target positive self-assessments of cognitive functioning with a total of 8 items. Raw scores can range from 8 to 40. The raw score is then converted to a t-score and higher scores indicate better perceived cognitive functioning.

    Time frame: 2-weeks (primary endpoint) follow up at 6 weeks

  5. Patient-Reported Outcomes Measurement Information System Cognitive Concerns

    items are worded negatively and express concerns in the same areas as in the Patient-Reported Outcomes Measurement Information System Cognitive Abilities with a total of 8 items. Raw scores can range from 8 to 40. The raw score is then converted to a t-score and higher scores indicate greater cognitive concerns.

    Time frame: 2-weeks (primary endpoint) follow up at 6 weeks

  6. Positive and Negative Affective Schedule (PANAS)

    consists of two 10-item mood scales to measure positive and negative affect. Raw scores range from 10 to 50. Higher scores indicate more of a positive affect.

    Time frame: 2-weeks (primary endpoint) follow up at 6 weeks

  7. The Composite Autonomic Symptom Score (COMPASS-31)

    consists of 31 items and measures autonomic and neurodegenerative system symptoms. Total scores range from 0 to 100 with greater scores indicating greater autonomic dysfunction.

    Time frame: 2-weeks (primary endpoint) follow up at 6 weeks

  8. The Functional Assessment of Chronic Illness Therapy Fatigue Scale (FACIT-F)

    13-item questionnaire designed to assess the severity of fatigue and its impact on daily functioning and quality of life. Respondents rate items on a 5-point scale, with higher scores indicating less fatigue. Total scores can range between 0 and 52.

    Time frame: 2-weeks (primary endpoint) follow up at 6 weeks

  9. Long-COVID Symptom Tool (Long-COVID ST)

    assess the symptoms of long COVID-19 created from patients' lived experience that measures 10 different physiological domains. Scores can range from 0 to 53 with higher scores indicating greater severity of symptoms.

    Time frame: 2-weeks (primary endpoint) follow up at 6 weeks

  10. Long-COVID Impact Tool (Long-COVID IT)

    assess the symptoms of long COVID-19 created from patients' lived experience that measures 10 different physiological domains. The scale also measures the impact from these symptoms. Scores can range from 0 to 60 with higher scores indicating greater life impact.

    Time frame: 2-weeks (primary endpoint) follow up at 6 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2026; primary completion for Sep 2026, 1 month later.

Of 232 non-industry interventional studies with no phase under Post-Acute COVID-19 Syndrome, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 28. This study's planned 1 month is below that.

Counting every sponsor, half of 243 studies reached it within 16 months; a quarter within 7 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 30, 2023
First posted
Jul 5, 2023
StartEst.
Aug 1, 2026
Primary completionEst.
Sep 30, 2026
CompletionEst.
Dec 1, 2026
Last update
Nov 13, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 13, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05931497
Responsible party
Maren Nyer (Clinical Psychologist, Massachusetts General Hospital) — Principal investigator
First posted
Jul 5, 2023
Start date
Aug 1, 2026 (estimated)
Primary completion
Sep 30, 2026 (estimated)
Completion
Dec 1, 2026 (estimated)
Last update
Nov 13, 2025

Study contacts

Maren Nyer, PhD
Contact
mnyer@mgh.harvard.edu
6072796290
David Mischoulon, MD, PhD
Contact
dmischoulon@mgh.harvard.edu

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion